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FUNCTIONALIZED NANOCERIA 
COMPOSITION FOR OPHTHALMIC 
TREATMENT 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
This is a division of U.S. application Ser. No. 13/154,849, 
filed on Jun. 7, 2011, which is a division of U.S. application 
Ser. No. 12/147,759, now U.S. Pat. No. 7,959,949, filed Jun. 
27, 2008 and issued Jun. 14, 2011, which claimed priority 
from U.S. provisional application Ser. No. 60/946,815, filed 
Jun. 28, 2007, and is also a continuation in part of U.S. 
application Ser. No. 11/412,665, now U.S. Pat. No. 7,727, 
559, filedApr. 27, 2006 and issued Jun. 1, 2010. Each of these 15 
documents is incorporated by reference in its entirety. 
to the nanoparticles, the ocular bioavailability of many drugs 
is significantly enhanced in comparison to normal aqueous 
eye drop solutions.12 Also, smaller particles improve patient 
comfort during administration as a scratchy feeling tends to 
occur with larger particles. Nanoparticles and microspheres 
of various synthetic polymers such as poly-butylcyanoacry-
late, 15016 poly lactic acid, 1 7 polymethy lmethacry late, 16 and so 
forth as well as natural biocompatible polymers like albu-
min18•19 have been used for ophthalmic drug delivery appli-
lO cations. 
STATEMENT OF GOVERNMENT RIGHTS 
SUMMARY OF THE INVENTION 
With the foregoing in mind, in one embodiment, the 
present invention advantageously provides a composition 
comprising a plurality of nanoceria particles, a sufficient 
amount of at least one inhibitor of human carbonic anhydrase 
II associated with said plurality of nanoceria particles, and a 
The investigation leading to this application was supported 
at least in part by a grant from the National Science Founda-
tion. The government may, therefore, have some rights in the 
invention, as specified by law. 
20 pharmaceutically acceptable carrier containing said plurality 
of nanoceria particles with associated inhibitor. The at least 
one inhibitorofhuman carbonic anhydrase II preferably com-
prises 4-carboxybenzene sulfonamide. Preferably, the 
enzyme inhibitor is effective against human carbonic anhy-
FIELD OF THE INVENTION 
The present invention relates to the field of nanotechnology 
and, more particularly, to nanoceria particles which carry a 
medicinal drug. 
25 drase II and the composition is used in treating an eye disease, 
particularly glaucoma, by contacting the eye with the com-
position. 
The composition may also further comprise a detectable 
tag associated with the plurality of nanoceria particles. The 
BACKGROUND OF THE INVENTION 
30 skilled will recognize that the term "tag" indicates any atom 
or molecule which, when associated with the nanoceria, 
imparts a property which allows for tracking of the nanoceria 
during treatment. Tracking may be by any known method, for 
example, fluorescence responsive to ultraviolet light. In 
Countless individuals suffer from the ocular disease glau-
coma. This condition describes a destruction of optic nerve 
cells and deterioration of eyesight as a result of increased 
intraocular pressure. The pressure is caused in part by a 
buildup of carbon dioxide in the eye. An enzyme that aids in 
the production of C02 is human carbonic anhydrase II 
(hCAII). This Zn2+ containing metalloenzyme (FIG. 1) cata-
lyzes the reversible hydration of carbon dioxide to bicarbon- 40 
ate and is commonly found in living organisms. 
35 effect, the tag may be a fluorescent tag associated with said 
plurality of nanoceria particles and the fluorescent tag is 
preferably a fluorescein compound associated with said plu-
rality of nanoceria particles, in particular, carboxyfluores-
cem. 
Sulfonamide compounds have been shown to selectively 
inhibit hCAII even at low concentratons.1 Therefore, inhibi-
tion ofhCAII with sulfonamides constitutes one of the most 
physiological approaches for treatment of glaucoma. In 1958 45 
Beasley et al. reported the in vitro binding of 4-carboxyben-
zene sulfonamide (CBS) to the carbonic anhydrase (CA) 
enzymes.2 Since then, many other hCAII inhibitors based on 
this moiety have been reported.3 -5 A remarkable increase in 
the hCAII inhibition activity was observed for simple ali- 50 
phatic esters ofCBS.5 Also, it is now extensively documented 
that significant enhancement of CA inhibition can be 
achieved through coupling the primary recognition aromatic 
sulfonamide motif with secondary binding elements. 3 •5-9 The 
mechanism for inhibition ofhCAII by CBS involves coordi- 55 
nation of the sulfonamide group (as the anion) to the zinc 
atom in the active site of hCAII to form a complex in an 
exothermic reaction. 6, 10, 11. 
In ophthalmic diseases such as glaucoma, treatment with 
conventional liquid eye drops is an inefficient mode of 60 
therapy because oflachrymal drainage losses. Because of the 
high elimination rate, only a very small amount ofabout 1-3% 
of the dosage actually penetrates through the cornea and is 
able to reach intraoculartissues.12-14 Nanoparticles provide a 
promising potential as drug carriers for ophthalmic applica- 65 
tions. The colloidal nanoparticles may be applied in liquid 
form just like eye drop solutions. After optimal drug binding 
In this preferred embodiment of the invention, the nanoc-
eria particles are made by a method comprising a reaction 
according to Scheme IA, shown in FIG. 3. Moreover, the 
nanoceria particles associated with carboxyfluorescein are 
made by a method comprising a reaction according to 
Scheme 1B in FIG. 3. 
Another embodiment of the invention includes a composi-
tion comprising a plurality of nanoceria particles, a sufficient 
amount of at least one biologically active agent bound to said 
plurality of nanoceria particles, and a pharmaceutically 
acceptable carrier containing said plurality of nanoceria par-
ticles with bound inhibitor. Preferably, the biologically active 
agent comprises a medicinal drug and, particularly, an oph-
thalmically active drug, which could be an enzyme inhibitor. 
In particular, the biologically active agent could comprise a 
sulfonamide compound, especially one that inhibits human 
carbonic anhydrase. 
Another preferred embodiment of the invention includes a 
method of treating a patient's eye condition. The method 
comprises providing a composition containing a plurality of 
nanoceria particles associated with a drug and suspended in a 
pharmaceutically acceptable carrier, and contacting the 
patient's eye with the composition. 
In this embodiment, the drug preferably comprises an 
enzyme inhibitor and especially an inhibitor of human car-
bonic anhydrase. The eye condition comprises glaucoma and 
drug comprises 4-carboxybenzene sulfonamide. In the 
method, contacting the eye may be accomplished in any fash-
US 8,795,737 B2 
3 
ion known to the skilled but, typically would comprise a 
procedure selected from instilling, injecting, diffusing and 
combinations thereof. 
4 
invention to those skilled in the art. Other features and advan-
tages of the invention will be apparent from the following 
detailed description, and from the claims. 
Nevertheless, while this disclosure preferably comprises 
nanoceria compositions and treatments directed to eye con-
ditions and, particularly, to glaucoma, the invention includes 
within its scope the concept of associating a drug with the 
nanoceria particles as carriers. The range of drugs that can be 
employed in the invention is rather broad and includes any 
drug or pharmaceutical composition that can be complexed, 10 
associated with or otherwise bound to the nanoceria particles 
without significantly adversely affecting the biological activ-
The term "pharmaceutical composition" is used herein as 
commonly known by those skilled in the art and generally 
indicates a mixture containing ingredients that are compatible 
when mixed and which may be administered to a patient or 
biological system, whether human, animal or in vitro, in order 
to treat a condition or disease. A pharmaceutical composition 
may cause a degree of toxicity in the patient to whom it is 
administered but, typically, it would be given in a dosage form 
and/or amount that does not cause substantial harm to the 
patient or biological system being treated. Examples of this 
dichotomy would include pharmaceutical compositions for 
ity of the drug. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. 1 is a cartoon diagram showing the structure of human 
carbonic anhydrase; 
FIG. 2 depicts the molecular structure of (a) carboxyben-
zene sulfonamide (CBS) and (b) carboxylfluorescein (CBF); 
FIG. 3 depicts schemes for synthesis of functionalized 
nanoceria; (A) for nanoceria-CBS; and (B) for nanoceria-
CBS-CBF, according to embodiments of the present inven-
tion; 
FIG. 4 shows high-resolution XPS spectra forthe function-
alized nanoceria particles at various conjugation steps; (a) 0 
Is scan for epichlorohydrin-functionalized nanoceria; (b) 0 Is 
scan for the opened epoxide ring of epichlorohydrin; ( c) 0 Is 
scan for carboxybenzene sulfonamide-functionalized nanoc-
eria; and (d) C Is scan for carboxyfluorescein-functionalized 
nanoceria; 
FIG. 5 are images from confocal fluorescence microscopy 
of (a) bare nanoceria and (b) nanoceria with fluorophores; and 
FIG. 6 shows line graphs indicating the rate of hydrolysis 
of 4-nitrophenyl acetate by hCAII, determined using absor-
bance change at 400 nm, as a function of the nanoceria con-
centration. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
15 cancer chemotherapy, which are more toxic for cancer cells 
than for normal cells but, nevertheless, exert a level of toxicity 
on the patient's normal cells during treatment. A pharmaceu-
tical composition may include one or more medicinal drugs, 
which may or may not be prescription drugs. Additionally, the 
20 pharmaceutical composition may include carriers, solvents, 
adjuvants, emollients, expanders, stabilizers and other com-
ponents, whether these are considered active or inactive 
ingredients. The skilled will readily understand that the exact 
makeup of the composition will depend on the intended route 
25 of administration to the patient, for example, a composition 
intended for topical application to the skin will necessarily 
contain different components than one intended for oph-
thalmic instillation. Guidance for the skilled in preparing 
pharmaceutical compositions may be found in the U.S. Phar-
30 macopeia-National Formulary and other recognized treatises 
in the science of pharmacy. 
The figures illustrate the invention disclosed, which com-
prises inhibition of hCAII, a primary target enzyme for the 
treatment of glaucoma. Nanoceria, a nontoxic nanoparticle, 
35 was functionalized with hCAII inhibitors and was tested as a 
potential ophthalmic drug delivery tool. We have found vari-
ous applications of cerium oxide nanoparticles in biotechnol-
ogy. It was found that treatment with nanomolar concentra-
tions of cerium oxide nanoparticles increases cell longevity20 
40 and protects the cells from damages caused by X-ray radia-
tion21 and reactive oxygen species (ROS). These previous 
studies have revealed that nanoceria particles are nontoxic 
and exhibit favorable biocompatibility. 
Our studies related to use of nanoceria to protect the retina 
45 from oxidative stress caused by reactive oxygen species 
showed that the nanoparticles injected in the vitreous showed 
efficacy far away in the retina.22 Moreover, the nanoceria's 
uptake in 
human lung fibroblast cells was shown to be faster than the 
50 physical transport to the cell23 suggesting that these particles 
have favorable diffusive properties. Therefore, a composition 
of Ce02 nanoparticles was deemed as potentially very good 
candidate for serving as transport agent for the inhibitors. 
Since carbonic anhydrase n is a cytosolic enzyme, that is, it is 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 60 
In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, these illustrated 
embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
55 found in cellular cytoplasm, the inhibitor-functionalized 
nanoceria were synthesized to allow easy entry into living 
cells. 
The first step was to choose a molecule that can attach to 
the nanoceria and that can inhibit carbonic anhydrase. Car-
boxybenzene sulfonamide (CBS) (FIG. 2a) was the primary 
choice on the basis of the literature data, where it is shown that 
these benzenesulfonamides can serve as inhibitors of car-
bonic anhydrases and can possess favorable carboxyl groups 
for attachment.8024 It was hypothesized that binding these 
65 molecules to the nanoceria would create an effective inhibitor 
of carbonic anhydrase that can be transferred into the cytosol. 
Additionally, we also decided to attach a tracking compound, 
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a carboxyfluorescein molecule (FIG. 2b ), to visualize the cell 
permeation property of the nanoparticles through a confocal 
fluorescence microscope. 
6 
the scanning was subtracted by using a binding energy scale 
with the baseline set at 284.6 eV for the C (ls). 27 The XPS 
spectra were deconvoluted using PeakFit (version 4) soft-
ware. The surface concentration of various conjugates was 
158 evaluated from the integrated areas of the peaks corre-
sponding to the respective conjugates. 
Confocal Fluorescence Microscopy (CFM). 
The attachment of carboxybenzene sulfonamide and car-
boxyfluorescein molecules to nanoceria was confirmed using 
X-ray photoelectron spectroscopy (XPS). The formation of 
the fluorophore-functionalized nanoparticles was further 
established through confocal fluorescence microscopy. 
Finally, the derivatized nanoceria were tested as inhibitors of 
the recombinant hCAII enzyme. This was accomplished by 
observing the effect of nanoparticles on the rate of hCAII-
catalyzed hydrolysis of the substrate 4-nitrophenyl acetate.26 
Experimental Section 
An Olympus 161 Fluoroview IX 81 confocal fluorescence 
microscope was used. Imaging was performed on prepared 
10 
slides with nanoceria samples functionalized with carboxy-
fluorescein. The concentration of nanoceria was optimized to 
1 mg/mL of water for imaging. The emission and excitation 
wavelengths for carboxyfluorescein were determined to be 
15 520 and 480 nm, respectively. 
Ultraviolet-Visible Spectrophotometry (UV-vis). Functionalization of Cerium Oxide Nanoparticles 
(Scheme 1, FIG. 3) Cary 1E UV-vis spectrophotometer (UV-vis) from Varian 
Inc. was used to determine the inhibition potential of the 
nanoceria functionalized with the CBS. The enzyme activity Reaction of Ce02 Nanoparticles with Epichlorohydrin and 
Ammonia. 20 was measured in 25 mM HEPES buffer, pH 7.0 at 25° C., 
containing 10% acetonitrile. The concentration ofhCAII (ob-
tained from Sigma-Aldrich Company) was kept constant at 1 
uM for all the experiments. The concentration of the sub-
strate, 4-nitrophenyl acetate (in acetonitrile), was 1 mM for 
The 250 mg of cerium oxide nanopowder (obtained from 
Sigma-Aldrich Inc.) was suspended in 10 mL ofO. l M NaOH 
solution for 5 min. Then, 5 mL of epichlorohydrin was added, 
followed by the addition of 0.5 mL of 2 M NaOH. The 
suspension was stirred at room temperature for 6-8 h. The 
reaction mixture was then centrifuged, and the supernatant 
was decanted. The nanoparticles were washed by water fol-
lowed by centrifugation. This was done until the pH of the 
water was approximately 7 .0. The nanoceria powder was then 
dried under vacuum. Next, the nanopowder was again sus- 30 
pended in water, 25 mL of30% ammonium hydroxide solu-
tion was added, and the reaction mixture was stirred for 14 h. 
The product was purified by centrifugation, was washed with 
water, and was dried under vacuum again. 
25 experiments carried out with varying concentrations of func-
tionalized nanoceria and varied between 1 and 5 mM for the 
Reaction with Carboxybenzene Sulfonamide and Carboxy- 35 
fluorescein. 
The nanoparticles from the previous step were functional-
ized with the carboxybenzene sulfonamide and carboxyfluo-
rescein molecules. These molecules (either 200 mg, 1 mmol 
of the CBS orcarboxyfluorescein) were dissolved in 15 mL of 40 
dimethylformadide (DMF) and 5 mL of dichloromethane. 
Three hundred sevent-five microliters (3.5 mM) ofN-meth-
ylmorpholine (NMP) was added followed by the addition of 
442.5 mg (1 mmol) of the benzotriazol-1-yl-oxy-tris-(dim-
ethylamino) phosphonium hexafluorphosphage (BOP) 45 
reagent. The reaction mixture was stirred for 10 min at room 
temperature. The nanoparticles were then added. The mixture 
was stirred for approximately 20 hat room temperature. The 
reaction was stopped with 1 mL of water, and the mixture was 
centrifuged. It was then washed with DMF, water, and 50 
acetone three times each to get rid of the unattached carboxy-
fluorescein and finally was centrifuged. The nanoparticles 
were finally dried under vacuum. 
The carboxyfluorescein-functionalized nanoparticles were 
taken through the same procedure to attach additional CBS. 55 
This resulted in nanoparticles functionalized with carboxy-
benzene sulfonamide, as well as particles with both the CBS 
and carboxyfluorescein as shown in Scheme 1. 
X-ray Photoelectron Spectroscopy (XPS) 
The surface functionalization chemistry of the nanoceria 60 
was examined using a 5400 PHI ESCA (XPS) spectropho-
tometer. The base pressure during the XPS analysis was 
approximately 10-9 Torr, and Mg Ka X-radiation (1253.6 
eV) at a power of 200 W was used. The instrument was 
calibrated using a standard gold sample with the binding 65 
energy at 84.0±0.1 eV for Au (4f712). All the samples were 
placed on a carbon tape. Any charging shift produced during 
kinetic parameter determination studies with constant con-
centration of the functionalized nanoceria at 0.16667 mg/mL. 
The initial rates of 4-nitrophenyl acetate hydrolysis by hCAII 
were monitored spectrophotometrically, at 400 nm, using the 
Cary WinUV Kinetics application. The molar absorption 
coefficient, E of 18 400 M- 1 cm- 1 , was used to determine the 
concentration of 4-nitrophenolate formed by hydrolysis, as 
reported in the literature.28 
The substrate concentration dependent kinetic data in the 
absence and presence of functionalized nanoceria inhibitors 
was presented in the form of double reciprocal plots and was 
analyzed according to the Michaelis-Menten equation to 
obtain the Km and V max values. The inhibitor binding con-
stant, K,, for the functionalized-nanoceria inhibitors was 
determined according to the following relationship:29 
where, [I] is inhibitor (functionalized nanoceria) concentra-
tion; Km and Km, are Michaelis constants in the absence and 
presence of the inhibitor, respectively. 
Results 
The expected functionalization of nanoceria was con-
firmed by XPS. The attachments of the epichlorohydrin 
linker, the inhibitor, and the fluorophore were established by 
examining the high-resolution C (ls) andO (ls) XPS spectra. 
The attachment of the fluorophore-functionalized nanopar-
ticles was further confirmed by imaging using a confocal 
fluorescence microscope. 
Functionalization Chemistry Using X-Ray Photoelectron 
Spectroscopy (XPS). 
The carboxybenzene sulfonamide and carboxyfluorescein 
were conjugated by first attaching epichlorohydrin to the 
surface of nanoceria particles. This is a standard SN2 reaction 
where the oxygen atom of the nanoceria essentially replaces 
the chlorine atom of the epichlorohydrin.30 This results in an 
oxygen atom that bonds the cerium with the carbon of the 
epichlorohydrin as seen in the first reaction of Scheme 1, as 
shown in FIG. 3. 
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In case ofnanocrystalline cerium oxide, the 0 (ls) spectra 
contain two peaks corresponding to the mixed valence state of 
Ce (Ce3 + and Ce4 +) present in its crystal lattice. The peak at 
530.5 eV corresponds to Ce4 + while the higher binding 
energy peak at about 532.20 eV corresponds to Ce3 +- 31 The 
two additional peaks present in the spectra given in FIG. 4a 
demonstrate that the expected functionalization occurred. 
These peaks include the 0 (ls) line of the epichlorohydrin's 
epoxy group at 533.30 eV and the 0-C bond that connects 
the main part of the epichlorohydrin molecule to the cerium 10 
oxide at 534.10 eV.32 The high-resolution 0 (ls) XPS spectra 
thus indicate the successful attachment of the epichlorohy-
drin molecule to cerium oxide nanoparticles. The loading of 
epichlorohydrin on the ceria nanoparticles, calculated from 
the integrated areas of 0 peaks corresponding to epichloro- 15 
hydrin to those for Ce3 + and Ce4 +, was evaluated to be 3.18 
mmol/gm ofCe02. 
Ammonia was then used to open up the epoxide ring (SN2 
reaction) on the epichlorohydrin molecule to form amine 
(-NH2 ) and hydroxyl (-OH) groups available for further 20 
reactions (FIG. 3, Scheme 1 ). The indication that this reaction 
occurred lies in the diminishment of the peak at 533.30 from 
FIG. 4a. The new peak at 533.00 eV in FIG. 4b corresponds 
to the newly formed-OH groups.32 However, FIG. 4b also 
confirms that the 0---C bond that links the epichlrohydrin 25 
molecule bond to the nanoceria remained with the peak at 
534.00 eV. Thus, the epichlrohydrin was still attached to the 
nanoceria and the epoxide ring opened as expected. The inte-
grated area analysis of the peaks confirmed almost 100% ring 
opening for the epoxide group of the epichlorohydrin conju- 30 
gated to the cerium oxide nanoparticles. 
The nanoceria now possessed two functional groups that 
could be further functionalized by the carboxybenze sulfona-
mide and carboxyfluorescein molecules. Both of them have 
carboxyl groups that can react to the available amine and 35 
hydroxyl groups from the opened ring of the surface-func-
tionalized nanoceria (FIG. 2). The coupling reactions 
included standard peptide coupling reagents, N-methyl mor-
pholine (NM)) and benzotriazol-1-yl-oxy-tris (dimethy-
lamino) phosphonium hexafluorophosphate (BOP). The 40 
reactions were conducted in dimethylformamide (DMF), a 
polar aprotic solvent that facilitates the coupling. 
The attachment of the inhibitor, CBS, to the amine group 
was confirmed by the 0 ls XPS spectrum in FIG. 4c. The 
locations of all of the peaks essentially remained the same 45 
from the previous spectrum in FIG. 4b except for two addi-
tional peaks. These peaks at 531.13 and 531.70 eV corre-
spond to the double-bonded oxygen atoms of the C=O and 
S=O bonds, respectively, that are part of the CBS. The XPS 
analysis thus indicated that the inhibitor bonded to the nano- 50 
ceria particles. The loading yield determined from the decon-
voluted peak areas was evaluated to be 3.14 mmol/gm of 
Ce02 (98.8%). 
Instead of the 0 ls spectrum, the carbon (Cls) spectrum 
was used to confirm the attachment of carboxyfluorescein, 
because this large molecule shielded many of the oxygen 
peaks seen in the previous oxygen spectra. FIG. 4d shows the 
various peaks present in the XPS spectra corresponding to the 
different C positions in the structure of the carboxyfluores-
cein functionalized ceria nanoparticles. It confirms that the 
fluorophore was also attached successfully to the ceria nano-
particles via epichlorohydrin linkage. The XPS peak analysis 
gave the surface concentration of the fluorophore to be 6.0 
mmol/gm of Ce02 . The results of the high-resolution XPS 
spectra for all of the reactions are summarized in Table S 1 of 65 
the Supporting Information (not shown but incorporated 
herein by reference; this material is available to the public free 
55 
60 
8 
of charge via the Internet at http://pubs.acs.orq a web site of 
The American Chemical Society). 
Confocal Fluorescence Microscopy. 
Further evidence that the fluorescent molecules bonded 
was presented in the confocal fluororescence microscopy 
images. As seen in FIG. 4, the carboxyfluorescein-function-
alized nanoparticles were clearly visible under a confocal 
fluorescence microscope O'-ex =480 nm; "-em =520 nm) as 
green dots while the bare nanoceria resulted in images show-
ing a black background. An individual green dot represents a 
small agglomerate of the ceria nanoparticles (particle size: 
10-20 nm) successfully functionalized with carboxyfluores-
cein. This further demonstrates that the fluorophores were 
attached to the nanoceria. The procedure for attaching these 
fluorescent molecules can be used in future studies to track 
the nanoceria as they are inserted into living cells. Future 
studies will involve inserting these particles in vivo and track-
ing their movement as they approach the expected locations 
of enzymes. 
Inhibition Studies. 
The final facet of the study involved determining whether 
the functionalized nanoceria inhibited the recombinant 
hCAII enzyme. This was accomplished by observing the 
effect of nanoparticles on the rate of hCAII-catalyzed 
hydrolysis of the substrate 4-nitrophenyl acetate. Essentially, 
the nanoparticles were mixed with a solution of the 4-nitro-
phenyl acetate and enzyme. The UV-vis spectrophotometer 
then measured the absorbance values at 400 nm as 4-nitro-
phenylacetate was hydrolyzed to form 4-nitrophenolate. The 
change in the absorbance values at different concentrations of 
nanoceria indicated the inhibiting effect of the conjugated 
nanoparticles. 
The declining slopes in FIG. 6 reveal that, when the inhibi-
tor-functionalized nanoceria bound to the active site of 
hCAII, the rate of formation of 4-nitrophenolate from 4-ni-
trophenyl acetate decreased. A decrease in the rate of its 
formation produced a solution that became tinted at a slower 
rate, which was represented by the decrease in the absorbance 
values as a function of time (see FIG. 6). hCAII's activity 
declined with increased concentration of nanoceria, as indi-
cated by the decreasing rate for the hydrolysis of 4-nitrophe-
nyl acetate to 4-nitrophenolate. Bare nanoceria did not affect 
the rate of hydrolysis of 4-nitrophenyl acetate. When the 
inhibitor was paired with the fluorophore, the inhibition was 
better than with nanoceria functionalized only with CBS. The 
kinetic parameters (Km, V max and K,) for the functionalized 
nanoceria samples, determined using the double-reciprocal 
plots, are summarized in Table 1. 
TABLE 1 
Kinetic Parameters of the hCAII-Catalyzed Reaction in the Absence 
and Presence ofFWlctionalized-Nanoceria Inhibitors 
inhibitor Km(mM) V max (mM/min) K,(mg/mL) 
no inhibitor 115.23 ± 1.36 3.02 ±0.15 
nanoceria with inhibitor 125.40 ± 0.98 3.24 ± 0.08 1.89 ± 0.16 
(CBS) 
nanoceria with inhibitor 135.24 ± 1.10 3.12 ± 0.10 0.96 ± 0.09 
(CBS) and fluorophore 
( carboxyfluorescene) 
Discussion 
One of the emerging goals of nanotechnology is to func-
tionalize inert and biocompatible materials to impart precise 
biological functions. Several hybrid organic/inorganic nano-
particles have been described for diagnostic or therapeutic 
use,34035 including quantum dots,36037 polymers,38 and mag-
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netofluorescent nanoparticles.39 Although many coupling 
systems have been reported for polymeric nanoparticle con-
jugation with varying degrees of success,40•41 the coupling 
and functionalization ofinorganic nanoparticles with biomol-
ecules has only been carried out with a limited number of 
chemical methods. Niemeyer42 has written an elaborate 
review on usage of various coupling agents such as citrate, 
streptavidin, and various other complex linker molecules with 
amide and carboxylic acid end groups for coupling of inor-
ganic nanoparticles (Au, Ag, ZnS, CdS, Sn02 , Ti02 , etc.) and 10 
biomolecules (proteins, DNA, etc.). 
In this disclosure, we have shown the simultaneous conju-
gation of the hCAII inhibitor, CBS, and the fluorophore, 
carboxyfluorescein, to cerium oxide nanoparticles via 
epichlorohydrin as a linker molecule. Epichlorohydrin is a 15 
highly reactive compound used in manufacture of epoxy and 
phenoxy resins. It is also used as a solvent and in the synthesis 
10 
and quantitative observations further confirmed that the car-
boxyfluorescein molecules bonded to the nanoceria particles. 
These results are very promising, and more studies will likely 
evolve into an inhibition of hCAII in living cells and an 
effective treatment of glaucoma and other diseases. 
Furthermore, inhibitors for other disease associated 
enzymes can be immobilized on the nanoceria and then 
applied to the enzymes. The potential applications for func-
tionalized cerium oxide nanoparticles seem limitless as a 
potential nontoxic drug delivery tool. 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
That which is claimed is: 
1. A method of making nanoceria particles functionalized 
25 with a human carbonic anhydrase II inhibitor, the method 
of glycerol. Anirudhan et al.43 have developed a new adsor-
bent system for phosphate removal from wastewaters using 
epichlorohydrin to modify lignocellulosic residue. Also, it 20 
has been used in synthesis of lipopolyhydroxylalkylamines 
for gene delivery.44 Weissleder et al 0.45 cross-linked the 
monocrystalline magnetic nanoparticles, consisting of 3 nm 
core of (Fe2 0 3)n(Fe3 0 4 )m covered with a layer of dextran, 
with epichlorohydrin and aminated them by reaction with 
ammonia to provide primary amine groups for the parallel 
synthesis of a library comprising 146 nanoparticles decorated 
with different synthetic small molecules. Similarly, in the 
present study, epichlohydrin was attached to the ceria nano-
particles via a condensation reaction between the orga- 30 
nochloride group from epichlorohydrin and the surface 
hydroxyl groups of the nanoceria particles and then was ami-
nated to provide primary amine group for conjugation of 
enzyme inhibitor as well as the fluorophore to the nanoceria 
particles. The epichlorohydrin may have provided a spacer 35 
that allowed the inhibitor to reach the active site of the car-
comprising: 
(a) preparing amine functionalized cerium oxide nanopar-
ticles by (i) reacting cerium oxide and epichlorohydrin 
in an aqueous sodium hydroxide solution to form a 
cerium oxide nanoparticle reaction product, (ii) remov-
ing the cerium oxide nanoparticle reaction product from 
the aqueous sodium hydroxide solution, and (iii) placing 
the removed cerium oxide nanoparticle reaction product 
into an ammonium hydroxide solution; 
(b) attaching the human carbonic anhydrase II inhibitor to 
the amine functionalized cerium oxide nanoparticles by 
(i) adding NMP and BOP to a solution of the human 
carbonic anhydrase II inhibitor to form a reaction mix-
ture, (ii) mixing the amine functionalized cerium oxide 
nanoparticles with the reaction mixture, and (iii) sepa-
rating nanoceria particles functionalized with the human 
carbonic anhydrase II inhibitor. 
bonic anhydrase and to reduce any steric hindrance of the 
enzyme's interaction with the inhibitors on the surface of the 
nanoparticles. Furthermore, the inhibition was nearly directly 
proportional with increased concentration of the functional- 40 
ized nanoceria inhibitors (FIG. 6). The analysis of the kinetic 
data conformed to the competitive type of inhibition model. 
Higher Km values in the presence of functionalized nanoceria 
inhibitors than in its absence eliminate the possibility of 
"noncompetitive inhibition". In conclusion, these results 
demonstrate that inhibition of the hCAII enzyme can be 
achieved using nanoceria particles surface-functionalized 
with CBS. 
2. A method of making fluorescent nanoceria particles 
functionalized with a human carbonic anhydrase II inhibitor, 
45 the method comprising: 
The aim of the present application is to show that a suc-
cessful conjugation of the ceria nanoparticles can be carried 50 
out using epichlorohydrin as a linker molecule and that such 
conjugated nanoparticles can be used for hCAII inhibition 
along with fluorescence-imaging capabilities. The inhibition 
results may be further enhanced using multiprong surface-
binding groups. Our earlier studies in this regard have shown 55 
a potential strategy to improve inhibition ofhCAII by attach-
ing a surface-histidine recognition group to the inhibitor. Our 
on-going investigations include the usage of the same conju-
gation process for multiprong inhibitors of hCAII for 
improved results. 60 
CONCLUSION 
Nanoceria were successfully functionalized and tested as 
inhibitors for hCAII. High-resolution XPS C ls and 0 ls 65 
spectra were effectively utilized to follow the necessary steps 
in the reaction process. The fluorescence microscope images 
(a) preparing amine functionalized cerium oxide nanopar-
ticles by (i) reacting cerium oxide and epichlorohydrin 
in an aqueous sodium hydroxide solution to form a 
cerium oxide nanoparticle reaction product, (ii) remov-
ing the cerium oxide nanoparticle reaction product from 
the aqueous sodium hydroxide solution, and (iii) placing 
the removed cerium oxide nanoparticle reaction product 
into an ammonium hydroxide solution; 
(b) attaching carboxyfluorescein to the amine functional-
ized cerium oxide nanoparticles by (i) adding NMP and 
BOP to a solution of carboxyfluorescein to form a first 
reaction mixture, (ii) mixing the amine functionalized 
cerium oxide nanoparticles with the first reaction mix-
ture, and (iii) separating nanoceria particles functional-
ized with carboxyfluorescein; and 
( c) attaching the human carbonic anhydrase II inhibitor to 
the nanoceria particles functionalized with carboxyfluo-
rescein by (i) adding NMP and BOP to a solution of the 
human carbonic anhydrase II inhibitor to form a second 
reaction mixture, (ii) mixing the nanoceria particles 
functionalized with carboxyfluorescein with the second 
reaction mixture, and (iii) separating nanoceria particles 
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functionalized with carboxyfluorescein and the human 
carbonic anhydrase II inhibitor. 
* * * * * 
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